Aktienanalyse zu Candel Therapeutics Inc (CADL)CADLCandel Therapeutics Inc

Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Candel Therapeutics Inc is a good buy right now due to its recent clinical trial success, which showed a 50% survival rate beyond 24 months for patients, and a significant YTD change of +140.26%. The current price of $13.07 is well below the analyst price targets of $26 and $30, indicating substantial upside potential. However, the main risk is the company's negative earnings per share of -0.35 reported in the last quarter, which reflects ongoing financial challenges.